Elevation of KL-6 serum levels in clinical trials of tumor necrosis factor inhibitors in patients with rheumatoid arthritis: a report from the Japan College of Rheumatology Ad Hoc Committee for Safety of Biological DMARDs

By Harigai Masayoshi  

Modern Rheumatology, Vol. 23, Iss. 2, 2013-03 ,pp. : 284-296

Springer Publishing Company

Access to resources Recommend Favorite

Prospective study of HBV reactivation risk in rheumatoid arthritis patients who received conventional disease-modifying antirheumatic drugs

By Tan Jing  

Clinical Rheumatology, Vol. 31, Iss. 8, 2012-08 ,pp. : 1169-1175

Springer Publishing Company

Access to resources Recommend Favorite

Distribution of Podoplanin in Synovial Tissues in Rheumatoid Arthritis Patients Using Biologic or Conventional Disease-Modifying Anti-Rheumatic Drugs

By  

Current Rheumatology Reviews, Vol. 13, Iss. 1, 2017-01 ,pp. : 72-78

Bentham Science Publishers

Access to resources Recommend Favorite

Intensifying treatment of rheumatoid arthritis with combinations of traditional disease-modifying anti-rheumatic drugs among patients with persistent disease did not reduce the need for large joint surgery

By Kononoff A.   Heiskanen J.   Lumiaho J.   Kautiainen H.   Kaipiainen-Seppänen O.  

Scandinavian Journal of Rheumatology, Vol. 36, Iss. 6, 2007-01 ,pp. : 424-427

Informa Healthcare

Access to resources Recommend Favorite

Delayed treatment with tumor necrosis factor inhibitors in incomplete responders to synthetic disease-modifying anti-rheumatic drugs shows an excellent effect in patients with very early rheumatoid arthritis with poor prognosis factors

By Kita Junko  

Modern Rheumatology, Vol. 22, Iss. 2, 2012-04 ,pp. : 195-201

Springer Publishing Company

Access to resources Recommend Favorite